Royalty Pharma Plc - Asset Resilience Ratio

Latest as of March 2026: 0.11%

Royalty Pharma Plc (RPRX) has an Asset Resilience Ratio of 0.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RPRX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$21.90 Million

Cash + Short-term Investments

Total Assets

$19.82 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2000–2025)

This chart shows how Royalty Pharma Plc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Royalty Pharma Plc.

Liquid Assets Composition Over Time

This chart breaks down Royalty Pharma Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Royalty Pharma Plc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$21.90 Million	0.11%
Total Liquid Assets	$21.90 Million	0.11%

Asset Resilience Insights

Limited Liquidity: Royalty Pharma Plc maintains only 0.11% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Royalty Pharma Plc Industry Peers by Asset Resilience Ratio

Compare Royalty Pharma Plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Royalty Pharma Plc (2000–2025)

The table below shows the annual Asset Resilience Ratio data for Royalty Pharma Plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.10%	$18.80 Million	$19.62 Billion	-4.52pp
2024-12-31	4.62%	$841.97 Million	$18.22 Billion	+0.00pp
2023-12-31	4.62%	$756.74 Million	$16.38 Billion	+0.35pp
2022-12-31	4.26%	$717.04 Million	$16.81 Billion	-2.94pp
2021-12-31	7.21%	$1.26 Billion	$17.52 Billion	+2.55pp
2020-12-31	4.66%	$983.00 Million	$21.10 Billion	+0.27pp
2019-12-31	4.39%	$547.01 Million	$12.45 Billion	+0.33pp
2018-12-31	4.06%	$461.82 Million	$11.37 Billion	-83.35pp
2007-12-31	87.41%	$24.12 Million	$27.60 Million	+16.06pp
2006-12-31	71.35%	$5.60 Million	$7.85 Million	-11.60pp
2005-12-31	82.95%	$14.67 Million	$17.68 Million	+10.29pp
2004-12-31	72.66%	$4.80 Million	$6.61 Million	+64.34pp
2003-12-31	8.32%	$2.00 Million	$24.03 Million	-51.80pp
2002-12-31	60.12%	$16.45 Million	$27.37 Million	-17.18pp
2001-12-31	77.30%	$28.54 Million	$36.91 Million	+16.82pp
2000-12-31	60.48%	$24.42 Million	$40.37 Million	--

pp = percentage points

About Royalty Pharma Plc

NASDAQ:RPRX USA Biotechnology

Market Cap

$25.92 Billion

Market Cap Rank

#1033 Global

#439 in USA

Share Price

$58.47

Change (1 day)

-0.98%

52-Week Range

$34.90 - $63.96

All Time High

$63.96